BioSpace News Archive

Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that United States Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for a Phase 2 clinical trial studying lyo lucinactant

Allogeneic “off-the-shelf” chimeric antigen receptor-natural killer T cell (CAR-NKT) therapy platform could overcome many of the challenges of current autologous CAR-T therapies The CAR-NKT cell platform has tumor-homing properties and is unlikely to cause GvHD Phase 1 ANCHOR clinical study will enroll adult patients with relapsed/refractory (R/R) CD19 positive malignancies HOUSTON--( BUSINESS WIRE )-- Kuur Therapeutics, a leader i

Novocure’s virtual Research & Development Day on November 12 will highlight progress across clinical and developmental pipelines and introduce areas of focus in translational research ST. HELIER, Jersey--( BUSINESS WIRE )-- Novocure (NASDAQ: NVCR) announced today that it will host a virtual Research & Development Day for analysts and investors from 7:30 a.m. to 9:30 a.m. EDT on Thursday, November 12, 2020, to highlight progress across its clin

PainReform Ltd.today announced that following the closing of its initial public offering, it has commenced preparations for the launch of its pivotal Phase 3 clinical trials of PRF-110 for the treatment of post-operative pain.

- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the appointment of Robert A. Ingram as the Chairman of its Board of Directors. Brad Bolzon, Ph.D., Chairman and Managing Director at Versant Ventures and Black Diamond’s founding Chairman, will remain on the Company’s board. “As we welcome B

Biotricity Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, today announced the launch of its Bioflux® Direct Program.

BioLife Sciences Inc. (OTC Markets: BLFE) now offers intelligent, touchless vending machines and marketplaces as part of its lineup of innovative digital products designed to assist consumers in the wake of the recent ongoing health crisis.

BioCardia®, Inc. [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the issuance of U.S. Patent No: 10,780,248 for a “Radial and Transendocardial Delivery Catheter” that further protects the Helix™ Biotherapeutic Delivery System and enhances its cell therapy delivery capabilities.

TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that management will participate in a fireside chat at the Jefferies Cell Therapy Virtual Summit on Monday, October 5, 2020

Astellas Venture Management (President: Kazunori Maruyama, Ph.D, “AVM”), a wholly-owned venture capital subsidiary of Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Mission Bay Capital BioLabs (“MBC BioLabs”), a life-science incubator, today announced their second collaboration on the “Golden Ticket Competition”.